J&J to buy Actelion for $30 billion

ZURICH (Reuters) - Swiss biotech company Actelion said on Thursday it had agreed to be purchased by Johnson & Johnson in a $30 billion deal.

J&J to buy Actelion for $30 billion
Read More


Bagikan Berita Ini